Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk's GLP-1 Victoza Off To A Good Start

This article was originally published in The Pink Sheet Daily

Executive Summary

New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
Advertisement

Related Content

Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
Early Data Suggest Novo Nordisk's Long-Acting Insulin DegludecOn Par With Sanofi's Lantus
Early Data Suggest Novo Nordisk's Degludec Comparable To Sanofi's Lantus
Early Data Suggest Novo Nordisk's Long-Acting Insulin Degludec On Par With Sanofi's Lantus
Merck Financial Targets Remain On Track, Despite Generic Cozaar, Health Care Reform
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles

Topics

Advertisement
UsernamePublicRestriction

Register

PS070553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel